AtheroNeth - Consortium for personalised treatment of Atherosclerosis.
AtheroNeth is a national Dutch research consortium, sponsored by the Dutch Heart Foundation, that encompasses top research groups from all Dutch University Medical Centers.
Aim of AtheroNeth is to improve treatment of patients with ASCVD by deciphering distinct molecular phenotypes & developing innovative modalities based on multidimensional data sources that will improve patient stratification and lead to personalized therapy choices.
During the last decades, successful strategies have been developed to treat ASCVD targeting traditional and novel risk factors leading to an unprecedented arsenal to reduce (residual) cardiovascular disease burden. Unfortunately, current strategies are all aimed at adding novel therapeutic agents on top of the standard therapeutic moieties, adopting the one-size-fits-all dogma. This strategy has several major limitations including unaddressed heterogeneity of patients ignoring patients’ side-effects, lack of response to therapy and decreased compliance.
With AtheroNeth, we aim to bring forward stratification tools that help establish the actual cardiovascular risk of patients considering the differential disease pathways and evaluate their response-to-therapy. This will allow clinicians to better tailor the therapeutic regimens.
Current treatment: “One size fits all”
Stratified treatment: “Aim AtheroNeth”
The road to AtheroNeth
“AtheroNeth, Dutch University Medical Centers jointly combat atherosclerotic disease."
The work packages
AtheroNeth consists of four experimental workpackages that will start at the initiation of the consortium. The 5th translational workpackage will be a call for proposals that aim to translate findings from WP1-WP4 (e.g. identified biomarkers or imaging parameters) to clinical practice. The 6th workpackage entails the strategy for talent development, ethics, diversity, dissemination, implementation and valorisation.
Work package 1
Plaque diversity and biomarkers (patient specific mechanisms).
Work package 2
Fundamental insights in mechanisms driving atherosclerosis diversity.
Work package 3
Cohorts and translation.
Work package 4
Imaging diversity (in interventions).
Work package 5
Translation to treatment.
Work package 6
Talent, dissemination, communication, impact, valorisation, administration.
